Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
NCT00061425 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL
Last updated 2021-08-19
Summary
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
Conditions
- Non-Hodgkin's Lymphoma
- Lymphoma, B-Cell
Interventions
- DRUG
-
radiolabeled epratuzumab
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
William Wegener · Gilead Sciences
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-08-31
- Primary Completion
- 2007-11-30
More Related Trials
-
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
NCT00553501 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
NCT00059904 ·Status: COMPLETED ·Phase: PHASE2
-
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
NCT06834373 ·Status: RECRUITING ·Phase: PHASE2
-
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
NCT00003338 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00003605 ·Status: WITHDRAWN ·Phase: PHASE2
-
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
NCT04609046 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
NCT00048555 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
NCT00002681 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
NCT00003874 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
NCT00398372 ·Status: COMPLETED ·Phase: NA
-
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003849 ·Status: COMPLETED ·Phase: PHASE2
-
Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
NCT00906841 ·Status: TERMINATED ·Phase: PHASE2
-
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
NCT00438880 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
NCT00003337 ·Status: UNKNOWN ·Phase: PHASE3
-
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
NCT00695786 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT01145495 ·Status: COMPLETED ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
NCT00003741 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab
NCT00208975 ·Status: TERMINATED ·Phase: PHASE2
-
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00005592 ·Status: COMPLETED ·Phase: PHASE2
-
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
NCT00045877 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
NCT01318317 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00033423 ·Status: TERMINATED ·Phase: PHASE1
-
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00301821 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00117975 ·Status: COMPLETED ·Phase: PHASE2